Training, Instinct & Careful Decision-Making Key to Active Shooter Response
On April 30, 2017, crews from the San Diego Fire Department (SDFD) and American Medical Response were dispatched to a shooting at an apartment complex in La Jolla, an upscale seaside community in San Diego not typically associated with violent crime. Early citizen reports to dispatchers didn't paint a clear picture of what crews would be called upon to manage: a hostile and dangerous active shooter incident at a poolside birthday party. Active shooter incidents seem to have become the norm in the U.S. and other countries, occurring at soft targets such as a movie theatre in Aurora, Colo., an elementary school in Ne...
Source: JEMS Operations - September 1, 2017 Category: Emergency Medicine Authors: Carolyn Gates, EMT-P, FP-C Tags: Major Incidents WMD & Terrorism Operations Source Type: news

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company ’s New Drug Application (NDA)...
Source: Drugs.com - New Drug Applications - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

No longer lost in translation
(La Jolla Institute for Allergy and Immunology) Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses. As a result, insights gained in the lab may be lost in translation. In their latest study, researchers at La Jolla Institute for Allergy and Immunology, developed a new approach to model human immune variation in the lab that overcomes the limitations of traditional mouse models.
Source: EurekAlert! - Cancer - July 26, 2017 Category: Cancer & Oncology Source Type: news

DermTech Secures Billing Codes for its Proprietary Melanoma Test
LA JOLLA, Calif., July 13, 2017 -- (Healthcare Sales & Marketing Network) -- DermTech, Inc., the global leader in non-invasive molecular dermatology, reported today that the American Medical Association (AMA) has granted the company Category 1, Tier 2 Mol... Diagnostics, Oncology, Reimbursement DermTech, Pigmented Lesion Assay, melanoma
Source: HSMN NewsFeed - July 13, 2017 Category: Pharmaceuticals Source Type: news

50-year-old flu virus model revamped, revealing pandemic prediction possibilities
(University of Pittsburgh Schools of the Health Sciences) The scientific textbook depiction of the flu virus is about to get a facelift, due to a University of Pittsburgh School of Medicine team's discovery that a model of the influenza genome architecture untouched since the 1970s isn't so perfect after all. The finding could give scientists the opportunity to better predict pandemics and find new ways to disrupt the flu virus.
Source: EurekAlert! - Infectious and Emerging Diseases - July 13, 2017 Category: Infectious Diseases Source Type: news

Strawberries may prevent age-related mental decline  
Researchers from Salk's Cellular Neurobiology Laboratory in La Jolla, California, found that mice fed fisetin experienced less cognitive deterioration and inflammation than untreated animals.
Source: the Mail online | Health - July 11, 2017 Category: Consumer Health News Source Type: news

K2M win FDA 510(k), CE Mark for Nile proximal fixation device
K2M (NSDQ:KTWO) said today it won FDA 510(k) clearance and CE Mark approval in the European Union for its Nile proximal fixation spinal system designed for proximal construct augmentation. The Nile system is designed to address complex spinal deformities and consists of bands and connectors to be used in conjunction with spinal rod constructs to attach to the posterior vertebral structures at the proximal end of the construct, the Leesburg, Va.-based company said. “I have used many band technologies for proximal construct augmentation from different companies and Nile Proximal is a huge leap forward in simplifying ...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Spinal K2M Source Type: news

Skincare, facelift and more: Top tips to help you glow this summer
THIS week we ’ve answered questions that have been sent in by readers or asked in our clinic.
Source: Daily Express - Health - July 6, 2017 Category: Consumer Health News Source Type: news

Nigeria: HIV Vaccine Moves One Step Closer to Reality
[Vanguard] SCIENTISTS from The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) may have found the best delivery mode for a vaccine against HIV.
Source: AllAfrica News: HIV-Aids and STDs - July 6, 2017 Category: Infectious Diseases Source Type: news

Liberia: Ganta Hospital to Modernize or
[Observer] Ganta United Methodist Hospital Administrator Patrick Martor. Since last year the GUMH has been under renovation, giving the hospital a much needed facelift.
Source: AllAfrica News: Health and Medicine - June 29, 2017 Category: African Health Source Type: news

Tumor immune fitness determines survival of lung cancer patients
(La Jolla Institute for Allergy and Immunology) In recent years, immunotherapy, a new form of cancer therapy that rouses the immune system to attack tumor cells, has captivated the public's imagination. When it works, the results are breathtaking. But more often than not it doesn't, and scientists still don't know why.
Source: EurekAlert! - Cancer - June 19, 2017 Category: Cancer & Oncology Source Type: news

Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
LA JOLLA, Calif., June 13, 2017 -- (Healthcare Sales & Marketing Network) -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promo... Biopharmaceuticals, Personnel Regulus Therapeutics, microRNA
Source: HSMN NewsFeed - June 13, 2017 Category: Pharmaceuticals Source Type: news

Regulus Announces Pipeline Updates and Advancements
Phase II RG-012 HERA and Renal Biopsy studies for Alport syndrome move forward Discontinuing clinical development of RG-101 Pre-clinical pipeline progresses LA JOLLA, Calif., June 12, 2017 -- (Healthcare Sales & Marketing Network) -- Regulus Ther... Biopharmaceuticals Regulus Therapeutics, microRNAs
Source: HSMN NewsFeed - June 12, 2017 Category: Pharmaceuticals Source Type: news

The Desperate Gambit That Could Save A Tiny Porpoise From Extinction ... Or Kill It
In 2016, scientists made a distressing announcement: There were fewer than 30 vaquitas ― a tiny porpoise that dwells in Mexico’s Gulf of California ― left in the wild. With carcasses continuing to wash up, researchers worry the vaquita could be extinct by 2018, becoming yet another mammal forced off the face of the Earth.  Losing the porpoise would be a tragedy for Mexico, the World Wildlife Fund said this week ― akin to “losing a piece” of the country, according to Maria Jose Villanueva, a project coordinator for WWF Mexico. But the demise of the vaquita would be a blow to more than...
Source: Science - The Huffington Post - May 22, 2017 Category: Science Source Type: news

15 Great White Sharks Off California Beaches Trigger Warnings
After a chilling sighting Wednesday, a Southern California sheriff’s deputy warned people from a helicopter to get out of the water because “you are paddleboarding next to approximately 15 great white sharks.” The lurking shadows of the big fish were spotted close to the surf line from Capistrano Beach in Dana Point to San Onofre State Beach, south of Los Angeles along the Orange County coast. Paddleboarders and swimmers were told to “exit the water in a calm manner.” The deputy added: “Please do not enter the water.” A swimmer reported a close encounter with one of the sharks, whi...
Source: Science - The Huffington Post - May 12, 2017 Category: Science Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20